A Study of fafety tolerabolity and clinical activitiy of MEDI4736 and Tremelimumab administered as monotherapy and in combination to subjects with unresectable heptocellular carcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
MedImmune, Inc.
Start Date
December 1, 2015
End Date
November 30, 2021
Administered By
Duke Cancer Institute
Awarded By
MedImmune, Inc.
Start Date
December 1, 2015
End Date
November 30, 2021